Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function

Model scores of the 29,894 trials active now.

Model score 7% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (233 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2011-11-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: in subjectssubjects withfunctionthe subjectchildbearing potential
  Phrases that lowered it: the pharmacokineticskgvolunteerspharmacokinetics ofmale
• Phase: 1 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 310 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 66.7% (lowers risk) · Drug's FDA history
• Drug's FAERS reports with a death: 0% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Disease area, neurology: No (lowers risk) · Disease area
• Number of arms: 4 (lowers risk) · Design
• Sponsor's past termination rate: 7.8% (raises risk) · Sponsor's track record
• Maximum age: 80 (raises risk) · Who can join
• Blinding: none (lowers risk) · Design
• Sponsor's past trials: 980 (raises risk) · Sponsor's track record
• Primary purpose: basic science (lowers risk) · Design
• Disease area, urogenital: Yes (raises risk) · Disease area
• Keywords listed: 9 (raises risk) · Design
• Disease area, psychiatry: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study in Healthy Volunteers to Investigate the Effects of Ketoconazole on the Pharmacokinetics of NKTR-118 NCT01520896 · started 2012 · scored riskier than 2% of active trials completed
• Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function NCT02959138 · started 2016 · scored riskier than 3% of active trials completed
• Effect of Renal Impairment on the Pharmacokinetics of NN9535 NCT00833716 · started 2009 · scored riskier than 10% of active trials completed
• Lorlatinib Renal Impairment Study NCT03542305 · started 2018 · scored riskier than 5% of active trials completed
• Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants. NCT05282030 · started 2022 · scored riskier than 10% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.